Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
about
Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factorsDiabetes outfoxed by GLP-1?Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetesIncreased islet apoptosis in Pdx1+/- miceMechanisms of action of glucagon-like peptide 1 in the pancreasExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectivesSomething old, something new and something very old: drugs for treating type 2 diabetesUse of glucagon-like peptide-1 agonists to improve islet graft performanceStructure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptorsDevelopment of diabetes mellitus in aging transgenic mice following suppression of pancreatic homeoprotein IDX-1GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cellsLiraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic miceHeterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replicationGlucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signalingLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesProtection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.TNF-like weak inducer of apoptosis (TWEAK) promotes beta cell neogenesis from pancreatic ductal epithelium in adult mice.A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique.Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsSlow and steady is the key to beta-cell replication.Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicityDo Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival.Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptidesMetabolic programming: causes and consequences.New therapeutic approaches to type 1 diabetes: from prevention to cellular or gene therapies.Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.PARP-1 and YY1 are important novel regulators of CXCL12 gene transcription in rat pancreatic beta cellsPancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.Incretin-based therapies in prediabetes: Current evidence and future perspectivesEffects of dietary fibers on weight gain, carbohydrate metabolism, and gastric ghrelin gene expression in mice fed a high-fat diet.Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trialThe role of incretins in glucose homeostasis and diabetes treatment.In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion.
P2860
Q24301709-CFC05571-8596-4FEB-B4EC-34FA8C8EABF3Q24603443-3759CD9C-0016-41EB-8360-EC6BDC6B5739Q24633002-7212149D-5CB0-41A7-8CB5-40A86EE42954Q24683719-F9C36FBF-CBAA-4970-990D-BA3258B8626BQ24683764-8750103E-961B-4008-87BC-95DA470D1B89Q26797236-5D842B61-695C-40F2-96EF-2FC91D180239Q26865663-EFE1C771-6AA8-449B-94CA-32C220AA16D1Q27013927-8AED4433-80CE-4B6E-A7DA-FBD452F2BC17Q28203273-3E42EFBF-FE28-4627-9C81-5ACF5E8F6FC5Q28344155-121AF536-3100-474D-ACCA-C64EAC9F804EQ28506327-A6AC4F6B-764F-4C36-BE92-883503CFE915Q28546996-953AFACA-DD9E-4430-97BC-92C438B3492EQ28552845-8155E22D-62C8-4125-A0A1-59E38EF4D86FQ28568760-47DFE61D-FF6E-4EE3-BC7B-2950B2F6CAAFQ28581928-70B53B6A-3939-411C-B86D-8C35ADB90941Q28728101-E3A54D9D-6D89-46EF-B6F4-E21D16BE5D8EQ28762629-D8C17B31-C353-43F7-BE67-7193323A0D97Q30390165-F61D9F22-951C-45D0-B50C-5B5D561DC35BQ31132382-C9F65850-4ADD-41A8-9F4F-8D86E6A3F522Q33268721-BBF0AC69-F4C2-46C1-A82F-2121B3F90CEFQ33305182-634D99CA-B686-40C3-A9BD-579419F2249BQ33521451-71AB6D75-F2C5-44BD-83EF-CF72F1A1CDEAQ33647542-0CCC5A9C-7B66-4DF5-9EC2-3D1487F20BCCQ33712562-B92E8BC7-EA09-452A-8955-632F77A8B806Q33789529-10491B81-ADDC-4BB2-BE91-D1F1FC2A9BCCQ33815664-DF641E0B-E908-4F58-9357-954237D4F667Q34003019-42995C5A-D5FE-4D8A-947C-40B185606BB0Q34026346-BE0BA344-020D-479A-BE02-91100A932C3FQ34037472-6ACD6725-77B6-45A6-8D54-9E0F714A1B15Q34128861-136BDB1A-DDBA-4FE6-B7A1-D9475C4A85ADQ34430909-18A8F0AE-DED9-4587-A80C-E62772348336Q34564255-C7972808-3C11-4067-A714-3557FDE4882BQ34648201-79291DD5-EC3A-4D08-86D3-B0A8DEA7F7CCQ34651839-94115573-45E8-4D94-AC96-8033FC14BCCFQ34656874-21FCEF72-7CAD-40FB-BBBC-4A83360DFF8FQ34699191-F92BBA8E-B4D6-46A1-8641-5B8D83E8C2B0Q34712822-90C067CA-C83E-48B8-A883-59BC7D3D6D0FQ34745045-300BB750-F263-4F20-A572-1C606269F93AQ34901533-C40BEE37-788D-4C5C-B7B2-E9BAF39E661BQ34967985-798AB064-CF89-4CF0-BB32-F393E536D2A2
P2860
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@en
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@nl
type
label
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@en
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@nl
prefLabel
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@en
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@nl
P2093
P1433
P1476
Insulinotropic glucagon-like p ...... islet size in mouse pancreas.
@en
P2093
Bonner-Weir S
Drucker DJ
Habener JF
Hussain MA
Kieffer TJ
Stoffers DA
P304
P356
10.2337/DIABETES.49.5.741
P407
P577
2000-05-01T00:00:00Z